Contacts and partners
We are working with colleagues in the wider NHS, regulatory and industry bodies as well as academic partners to explore COVID-19 research and trials.
If you have questions about donation to the plasma programme, you can phone, text or email us.
Go to contact us
Our programme partners
Government departments, agencies and public bodies
Department of Health & Social Care
Public Health England
National Institute for Health Research
Universities and departments
University of Cambridge
King's College London
University of Oxford
Radcliffe Department of Medicine
Nuffield Department of Medicine
Nuffield Department of Surgical Sciences
Wellcome Trust Centre for Human Genetics
Guy's and St Thomas' NHS Foundation Trust
John Radcliffe Hospital
Blood donation services
Scottish National Blood Transfusion Service
Welsh Blood Service
Royal College of Pathologists
British Society of Haematology
This ground-breaking REMAP-CAP trial, conducted by NHSBT, will test whether convalescent plasma treatment can save lives and shorten intensive care unit stays.
Professor David Menon
Emeritus Senior Investigator, National Institute for Health Research
NHS Blood and Transplant is now collecting convalescent plasma for use in a randomised clinical trial as a potential treatment for COVID-19. We are investigating whether this plasma can improve survival and reduce ventilation and intensive care unit stay in COVID-19 patients. This is an exciting development as there is no proven treatment for COVID-19.
Professor David Roberts
Associate Medical Director, NHS Blood and Transplant
The REMAP-CAP trial has been specifically designed to provide answers about the best treatment options for the most seriously ill with COVID-19. It is fully adaptive, meaning that new treatments can be added as we learn more, the sample size isn’t fixed and it keeps recruiting until it finds that a treatment is better, worse, or the same as another.
Professor Anthony Gordon
NIHR Research Professor and Chief Investigator for REMAP-CAP